DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting
11 Juin 2025 - 10:30PM
Châtillon, France, June 11, 2025
DBV Technologies Announces the Voting
Results of its 2025 Combined General Meeting
Shareholders approved all proposed
resolutions
DBV Technologies (Euronext: DBV – ISIN:
FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage
biopharmaceutical company (the “Company”), held
its Combined General Meeting (the “General
Meeting”). The General Meeting was chaired by Michel de
Rosen, Chairman of the Company.
The Company’s shareholders approved all
resolutions submitted by the Board of Directors. The resolutions
and the voting results are posted on the Investors/Annual General
Meetings section of the Company’s website:
https://dbv-technologies.com/events/2025-annual-general-meeting/.
About DBV TechnologiesDBV
Technologies is a clinical-stage biopharmaceutical company
developing treatment options for food allergies and other
immunologic conditions with significant unmet medical need. DBV is
currently focused on investigating the use of its proprietary
technology platform, Viaskin™, to address food allergies, which are
caused by a hypersensitive immune reaction and characterized by a
range of symptoms varying in severity from mild to life-threatening
anaphylaxis. Millions of people live with food allergies, including
young children. Through epicutaneous immunotherapy (EPIT™), the
Viaskin platform is designed to introduce microgram amounts of a
biologically active compound to the immune system through intact
skin. EPIT is a new class of non-invasive treatment that seeks to
modify an individual’s underlying allergy by re-educating the
immune system to become desensitized to allergen by leveraging the
skin’s immune tolerizing properties. DBV is committed to
transforming the care of food allergic people. The Company’s food
allergy programs include ongoing clinical trials of Viaskin Peanut
in peanut allergic toddlers (1 through 3 years of age) and children
(4 through 7 years of age).
DBV Technologies is headquartered in Châtillon,
France, with North American operations in Warren, NJ. The Company’s
ordinary shares are traded on segment B of Euronext Paris (Ticker:
DBV, ISIN code: FR0010417345) and the Company’s ADSs (each
representing five ordinary shares) are traded on the Nasdaq Capital
Market (DBVT – CUSIP: 23306J309).
For more information, please visit
www.dbv-technologies.com and engage with us on X (formerly Twitter)
and LinkedIn.
Viaskin and EPIT are trademarks of DBV
Technologies.
Investor Contact Katie
MatthewsDBV Technologieskatie.matthews@dbv-technologies.com
Media ContactAngela Marcucci
DBV Technologiesangela.marcucci@dbv-technologies.com
DBV Technologies (EU:DBV)
Graphique Historique de l'Action
De Juin 2025 à Juil 2025
DBV Technologies (EU:DBV)
Graphique Historique de l'Action
De Juil 2024 à Juil 2025
